Skip to main content
SpringerLink
Log in

Surrogate Markers of Resectability in Patients Undergoing Exploration of Potentially Resectable Pancreatic Adenocarcinoma

  • original paper
  • Published:
Journal of Gastrointestinal Surgery Aims and scope

Abstract

Despite extensive preoperative staging, a significant number of pancreatic cancers are unresectable at surgical exploration. Patients undergoing pancreatic exploration with a view to resection were studied and comparisons are then made between those undergoing resection and a bypass procedure to identify surrogate markers of unresectability. One hundred thirteen consecutive patients underwent pancreatic exploration for head-of-pancreas (HOP) adenocarcinoma with curative intent. Fifty-five underwent pancreaticoduodenectomy and 58 underwent a bypass procedure. Student’s t test, receiver operator characteristics (ROC) and logistic regression were used to compare the predictive value of preoperative patient variables collected retrospectively. The bypass group had a significantly higher median CA19.9 than the resection group (P = 0.003). Platelet count and neutrophil–lymphocyte ratio (NLR) were also significantly different (P = 0.013 and P = 0.026, respectively). ROC analysis indicated that age ≤65, platelet count >297 × 109/l, CA19.9 ≤473 Ku/l, and CA19.9–bilirubin ratio were predictive variables for resectable disease. NLR and CA19.9–bilirubin ratio had specificity values of 92.9 and 97.0%, respectively. From logistic regression, a raised CA19.9 was found to be an independent risk factor for unresectable disease (P = 0.031). A significant proportion of patients with HOP adenocarcinoma are understaged preoperatively. Preoperative serology including platelet count, NLR, CA19.9, and CA19.9–bilirubin ratio may be used as additional discriminators of resectability particularly for high-risk patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

Similar content being viewed by others

References

  1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:1049–1057.

    Article  PubMed  CAS  Google Scholar 

  2. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 1997;226:248–257.

    Article  PubMed  CAS  Google Scholar 

  3. Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, Mann CD, Berry DP. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007;33:892–897.

    PubMed  CAS  Google Scholar 

  4. Zacharias T, Jaeck D, Oussoultzoglow E, Neuville A, Bachellier P. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007;11(3):350–356.

    Article  PubMed  Google Scholar 

  5. Soriano A, Castells A, Ayuso C, Ayuso JR, de Caralt MT, Gines MA, Real MI, Gilabert R, Quinto L, Trilla A, Feu F, Montanya X, Fernandez-Cruz L, Navarro S. Preoperative staging and tumor resectability assessment of pancreatic cancer: Prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging and angiography. Am J Gastroenterol 2004;99(3):492–501.

    Article  PubMed  Google Scholar 

  6. Camacho D, Reichenbach D, Guerr GD, Venema TL, Sweeney JF, Fisher WE. Value of laparoscopy in the staging of pancreatic cancer. JOP 2005;6(6):552–561.

    PubMed  Google Scholar 

  7. Long EE, Van Dam J, Weinstein S, Jeffrey B, Desser T, Norton JA. Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer. Surg Oncol 2005;14(2):105–113.

    Article  PubMed  Google Scholar 

  8. Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19.9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006;49(4):241–244.

    PubMed  Google Scholar 

  9. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138(9):951–955.

    Article  PubMed  Google Scholar 

  10. Karachristos A, Scarmeas N, Hoffman JP. CA19.9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005;9(9):1286–1292.

    Article  PubMed  Google Scholar 

  11. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA19.9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215(4):350–355.

    Article  PubMed  CAS  Google Scholar 

  12. Lowe D, Lee J, Schade R, Chaudhary A. Patient with markedly elevated CA19.9 not associated with malignancy. South Med J 2006;99(3):306–308.

    Article  PubMed  Google Scholar 

  13. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19.9: Clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26(5):474–479.

    Article  PubMed  CAS  Google Scholar 

  14. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91(3):181–184.

    Article  PubMed  CAS  Google Scholar 

  15. Cook EJ, Walsh SR, Farooq N, Alberts JC, Justin TA, Keeling NJ. Post-operative neutrophil–lymphocyte ratio predicts complications following colorectal surgery. Int J Surg 2007;5(1):27–30.

    Article  PubMed  Google Scholar 

  16. Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow? Lancet 2001;357(9255):539–545.

    Article  PubMed  CAS  Google Scholar 

  17. Coussen LM, Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–867.

    Article  Google Scholar 

  18. Miyamoto Y, Hosotani R, Doi R, Wada M, Ida J, Tsuji S, Kawaguchi M, Nakajima S, Kobayashi H, Masui T, Imamura M. Interleukin-6 inhibits radiation-induced apoptosis in pancreatic cancer cells. Anticancer Res 2001;21:2449–2456.

    PubMed  CAS  Google Scholar 

  19. Hasselgren PO, Fischer E. Muscle cachexia: Current concept of intracellular mechanism and molecular regulation. Ann Surg 2001;233(1):9–17.

    Article  PubMed  CAS  Google Scholar 

  20. Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg 2005;189(3):278–282.

    Article  PubMed  Google Scholar 

  21. Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29(2):132–140.

    Article  PubMed  CAS  Google Scholar 

  22. Schwarz RE, Keny H. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma. Hepatogastroenterology 2001;48(41):1493–1498.

    PubMed  CAS  Google Scholar 

  23. House MG, Yeo CJ, Cameron JL, Campbell KA, Schulich RD, Leach SD, Hruban RH, Horton KM, Fishman EK, Lillemoe KD. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8(3):280–288.

    Article  PubMed  Google Scholar 

  24. Maemura K, Takao S, Shinchi H, Noma H, Mataki Y, Kurahara H, Jinnouchi S, Aikou T. Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13(5):435–441.

    Article  PubMed  Google Scholar 

  25. Mortensen MB, Edwin B, Hunerbein M, Liedman B, Neilsen HO, Hovendal C. Impact of endoscopic ultrasonography (EUS) on surgical decision-making in upper gastrointestinal tract cancer: An international multicenter study. Surg Endosc 2007;21(3):431–438.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatobiliary & Pancreatic Surgery, Leicester General Hospital, Gwendolen Road, Leicester, LE4 5PW, UK

    S. L. Ong, G. Garcea, S. C. Thomasset, C. D. Mann, C. P. Neal, M. Abu Amara, A. R. Dennison & D. P. Berry

Authors
  1. S. L. Ong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Garcea
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. C. Thomasset
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. D. Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. P. Neal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Abu Amara
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. R. Dennison
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D. P. Berry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. L. Ong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ong, S.L., Garcea, G., Thomasset, S.C. et al. Surrogate Markers of Resectability in Patients Undergoing Exploration of Potentially Resectable Pancreatic Adenocarcinoma. J Gastrointest Surg 12, 1068–1073 (2008). https://doi.org/10.1007/s11605-007-0422-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-007-0422-6

Keywords

Search

Navigation